83-5965-64　CD274, Durvalumab Biosimilar (B7-H1, PDL1) 5mg　591805

特徴

• Durvalumab is a humanized monoclonal antibody directed against the human protein ligand PD-L1 (B7-H1 or CD274, programmed cell death ligand 1).
• Durvalumab completely blocks the binding of PDL1 to both PD-1 and CD80, with IC50 of 0.1 and 0.04 nM, respectively.
• Durvalumab is an anticancer antibody that works to promote the antitumor response mediated by immune cells.
• By blocking the action of PD-L1, durvalumab exerts its anticancer effects by increasing T-cell activation, enhancing detection and ablation of tumor cells.
• In in vitro assays, durvalumab inhibited the activity of PD-L1 in a concentration-dependent manner.
• In co-engrafted human tumor and immune cell xenograft mouse models, durvalumab was effective in decreasing tumor size.
• Durvalumab does not mediate antibody-dependent cell-mediated cytotoxicity (ADCC).
• Applications:Suitable for use in ELISA, Neutralization, Functional Assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by Durvalumab.
• Other applications not tested.
• Recommended Dilution:Optimal dilutions to be determined by the researcher.
• Storage and Stability:May be stored at 4℃ for short-term only.
• Aliquot to avoid repeated freezing and thawing.
• Store at -20℃.
• Aliquots are stable for 12 months after receipt.
• For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.